Oral Tranexamic Acid After Total Knee Arthroplasty
Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively.
Hypothesis:
Patients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.